FibroGen Inc (NASDAQ:FGEN) – Stock analysts at Svb Leerink increased their FY2020 EPS estimates for FibroGen in a note issued to investors on Monday, November 11th. Svb Leerink analyst G. Porges now forecasts that the biopharmaceutical company will post earnings per share of $1.43 for the year, up from their previous estimate of $1.41.
FGEN has been the topic of several other research reports. TheStreet upgraded shares of FibroGen from a “d+” rating to a “c” rating in a research note on Tuesday, August 13th. ValuEngine upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $51.00 target price on the stock in a research report on Tuesday, August 13th. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. Finally, Mizuho restated a “positive” rating and set a $72.00 target price (up from $65.00) on shares of FibroGen in a research report on Monday. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $58.33.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.02. The business had revenue of $33.17 million for the quarter, compared to analysts’ expectations of $31.61 million. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.50) EPS.
Large investors have recently modified their holdings of the stock. Captrust Financial Advisors purchased a new stake in shares of FibroGen in the 2nd quarter worth approximately $90,000. US Bancorp DE lifted its position in shares of FibroGen by 79.7% in the 2nd quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 963 shares during the period. Usca Ria LLC purchased a new stake in shares of FibroGen in the 3rd quarter worth approximately $123,000. Convergence Investment Partners LLC purchased a new stake in shares of FibroGen in the 3rd quarter worth approximately $137,000. Finally, Nisa Investment Advisors LLC lifted its position in shares of FibroGen by 729.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 3,430 shares during the period. Institutional investors own 69.03% of the company’s stock.
In related news, SVP Christine Chung sold 11,250 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $43.17, for a total transaction of $485,662.50. Following the transaction, the senior vice president now directly owns 157,195 shares in the company, valued at approximately $6,786,108.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the transaction, the chief executive officer now owns 2,356,578 shares in the company, valued at $104,467,102.74. The disclosure for this sale can be found here. Insiders have sold a total of 86,756 shares of company stock worth $3,644,083 over the last 90 days. Corporate insiders own 7.83% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Story: Stocks Increasing Dividends
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.